Home » Stocks » INVA

Innoviva, Inc. (INVA)

Stock Price: $11.43 USD -0.19 (-1.64%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
Market Cap 1.16B
Revenue (ttm) 336.79M
Net Income (ttm) 224.40M
Shares Out 101.32M
EPS (ttm) 2.02
PE Ratio 5.66
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $11.43
Previous Close $11.62
Change ($) -0.19
Change (%) -1.64%
Day's Open 11.66
Day's Range 11.42 - 11.78
Day's Volume 677,068
52-Week Range 7.58 - 15.62

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 3 weeks ago

Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the fourth quarter.

Zacks Investment Research - 1 month ago

In the latest trading session, Innoviva (INVA) closed at $12.51, marking a +1.71% move from the previous day.

Zacks Investment Research - 1 month ago

Top Ranked Value Stocks to Buy for January 5th

Other stocks mentioned: CUBI, PAGP, SWBI
Zacks Investment Research - 1 month ago

Top Ranked Value Stocks to Buy for January 4th

Other stocks mentioned: DAC, MIK, ODP
Zacks Investment Research - 1 month ago

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to th...

Zacks Investment Research - 1 month ago

Top Ranked Value Stocks to Buy for December 29th

Other stocks mentioned: MIK, ODP
Zacks Investment Research - 1 month ago

Top Ranked Value Stocks to Buy for December 28th

Other stocks mentioned: AMRK
Zacks Investment Research - 1 month ago

To combat market volatility, create a portfolio of low-beta stocks.

Other stocks mentioned: CWT, EGOV, OMI, VSTO
Zacks Investment Research - 2 months ago

Top Ranked Value Stocks to Buy for December 24th

Other stocks mentioned: CLW, MIK
Forbes - 2 months ago

We believe that Innoviva stock, a pharmaceuticals royalty management company, is a good buying opportunity at the present time. INVA stock trades near $12 currently and it is, in fact, down 17...

Zacks Investment Research - 2 months ago

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to th...

Investopedia - 2 months ago

These are the biotech stocks with the best value, fastest growth, and most momentum for Q1 2021.

Other stocks mentioned: BDSI, BMRN, CPRX, NVAX, VRTX, VXRT, VYGR
Zacks Investment Research - 2 months ago

Top Ranked Value Stocks to Buy for December 7th

Other stocks mentioned: CPLP, QFIN
Zacks Investment Research - 2 months ago

To combat market volatility, it is of utmost importance to create a portfolio of low-beta stocks.

Other stocks mentioned: CWT, EGOV, OMI, SMP
Zacks Investment Research - 2 months ago

Top Ranked Value Stocks to Buy for December 3rd

Other stocks mentioned: AMRK, QFIN
Zacks Investment Research - 2 months ago

We have screened value stocks Amkor (AMKR), Innoviva (INVA), United States Cellular (USM), Old Republic (ORI) and Regal Beloit (RBC) based on EV-to-EBITDA ratio that offers a clearer picture o...

Other stocks mentioned: AMKR, ORI, RBC, USM
Zacks Investment Research - 2 months ago

Top Ranked Value Stocks to Buy for December 1st

Other stocks mentioned: DAC, QFIN, XAN
Zacks Investment Research - 2 months ago

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to th...

Zacks Investment Research - 3 months ago

Top Ranked Value Stocks to Buy for November 27th

Other stocks mentioned: DAC, ODP
Zacks Investment Research - 3 months ago

Top Ranked Value Stocks to Buy for November 24th

Other stocks mentioned: DAC, ODP, UNFI
Zacks Investment Research - 3 months ago

Top Ranked Value Stocks to Buy for November 19th

Other stocks mentioned: AMRK, NRIM, UNFI
Zacks Investment Research - 3 months ago

Top Ranked Value Stocks to Buy for November 17th

Other stocks mentioned: GPP, UNFI, XAN
Business Wire - 3 months ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) ("the Company") today reported financial results for the third quarter ended September 30, 2020. Gross royalty revenues of $9...

Forbes - 4 months ago

Stocks continued yesterday's rally on more stimulus optimism and strong earnings, although Goldman Sachs expressed doubts about the stimulus package. For investors looking to make sense of the...

Other stocks mentioned: CL, JBHT, PGR, WEX
Forbes - 4 months ago

Despite yesterday’s dip due to poor COVID vaccine and treatment news from Johnson and Johnson and Eli Lilly, the indices are up thus far in October. For investors looking to make sense of thes...

Other stocks mentioned: EPAM, LAUR, PGR, PRSP
The Motley Fool - 5 months ago

These stocks are just temporarily inconvenienced large caps in the making.

Other stocks mentioned: ADUS, SUPN
Investopedia - 5 months ago

These are the biotech stocks with the best value, fastest growth, and most momentum for Q4 2020.

Other stocks mentioned: GMAB, MRSN, NVAX, REGN, TECH, VNDA, XBIT
Zacks Investment Research - 5 months ago

With the approval for the asthma indication, Glaxo's (GSK) Trelegy becomes the first single inhaler triple therapy approved for the maintenance treatment of both asthma and COPD.

Other stocks mentioned: GSK
24/7 Wall Street - 5 months ago

The U.S. Food and Drug Administration (FDA) has approved Innoviva Inc.’s (NASDAQ: INVA) treatment of asthma and for patients with chronic obstructive pulmonary disease (COPD), the company anno...

Business Wire - 5 months ago

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced the US Food and Drug Administration (FDA) has approved a new indication for Trelegy Ellipta (fluticasone furoate...

Other stocks mentioned: GSK
Zacks Investment Research - 5 months ago

Innoviva (INVA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

The Motley Fool - 5 months ago

These shell companies allow the businesses they acquire to go public much more quickly than an IPO would. Is it time to buy in?

Other stocks mentioned: JAZZ, TBPH, TXAC, TXG
Forbes - 5 months ago

The Dow was lower this morning, on the day that they make major changes to their constituents after Apple's share split reduced tech influence in the index.

Other stocks mentioned: FBHS, LH, THO, WSM
Forbes - 6 months ago

All major indices are in the green as the investors digested the speech by the Federal Reserve, taken as positive for equities. Tech stocks have also been driving the markets higher, propellin...

Other stocks mentioned: D, GLT, VMC
The Motley Fool - 6 months ago

These two stocks are probably undervalued, but that won’t last forever.

Other stocks mentioned: ALXN
Business Wire - 6 months ago

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc.

Zacks Investment Research - 7 months ago

During Innoviva's (INVA) upcoming Q2 earnings call, investor focus will be on the royalties earned that comprise the company's top line.

GuruFocus - 7 months ago

Shareholders of Invesco Mortgage Capital Inc (NYSE:IVR) and Innoviva Inc (NASDAQ:INVA) have witnessed their stocks underperform the S&P 500 index over the past one-year, three-year and five-ye...

Other stocks mentioned: IVR
Zacks Investment Research - 8 months ago

Is (INVA) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 8 months ago

Innoviva (INVA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Zacks Investment Research - 8 months ago

Innoviva (INVA) closed at $14.13 in the latest trading session, marking a -0.77% move from the prior day.

Investopedia - 8 months ago

These are the biotech stocks with the best value, fastest growth, and most momentum for Q3 2020.

Other stocks mentioned: GMAB, IBB, NVAX, TRIL, VNDA, VRTX, XBIT
Zacks Investment Research - 8 months ago

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to th...

Zacks Investment Research - 8 months ago

Innoviva (INVA) closed the most recent trading day at $13.92, moving +0.43% from the previous trading session.

Zacks Investment Research - 8 months ago

Innoviva (INVA) closed at $14.36 in the latest trading session, marking a -1.64% move from the prior day.

Zacks Investment Research - 9 months ago

Is (INVA) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 9 months ago

As drug makers race to develop vaccine to fight coronavirus, we shortlist five stocks that are poised to grow on progress in clinical trials.

Other stocks mentioned: MRNA, SNY, GILD, PFE
Zacks Investment Research - 9 months ago

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to th...

Zacks Investment Research - 9 months ago

Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the first quarter.

Zacks Investment Research - 10 months ago

Top Ranked Momentum Stocks to Buy for April 16th

Other stocks mentioned: CASA, GFI, OCGN

About INVA

Innoviva engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonis... [Read more...]

Industry
Biotechnology
IPO Date
Oct 5, 2004
CEO
Geoffrey Hulme
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
INVA
Full Company Profile

Financial Performance

In 2020, Innoviva, Inc.'s revenue was $336.79 million, an increase of 29.03% compared to the previous year's $261.02 million. Earnings were $224.40 million, an increase of 42.67%.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for Innoviva, Inc. stock is "Strong Sell" and the 12-month stock price forecast is 10.00.

Price Target
$10.00
Analyst Consensus: Strong Sell